Abstract
Policymakers in different countries consider various aspects of orphan drug reimbursement. In Central and Eastern European (CEE) countries, some common characteristics can be seen when it comes to strategies for drug policy. We decided to investigate which aspects of the clinical data from orphan drugs might affect drug reimbursement in selected CEE countries.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
